Zobrazeno 1 - 10
of 41
pro vyhledávání: '"Jonathan C Fox"'
Autor:
Kelly L Roszko, Lyndsay M Stapleton Smith, Ananth V Sridhar, Mary Scott Roberts, Iris R Hartley, Rachel I Gafni, Michael T Collins, Jonathan C Fox, Edward F Nemeth
Publikováno v:
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 37(10)
Autosomal dominant hypocalcemia type 1 (ADH1) is a rare form of hypoparathyroidism due to activating variants of the calcium-sensing receptor gene (CASR). Inherited or de novo activating variants of the CASR alter the set point for extracellular calc
Autor:
John L. Berk, Graham Lohrmann, Omar K. Siddiqi, Deepa M. Gopal, Jennifer Hellawell, Mathew S. Maurer, Lawreen H. Connors, Roberta Mussinelli, Nirupama Vellanki, Alexandra Pipilas, Jonathan C. Fox, Frederick L. Ruberg
Publikováno v:
Journal of Cardiac Failure. 26:753-759
Background Transthyretin amyloidosis cardiomyopathy (ATTR-CM) is an underappreciated cause of heart failure that results from misfolded TTR (prealbumin) protein. Diflunisal is an approved non-steroidal anti-inflammatory drug that stabilizes TTR, with
Autor:
Uma Sinha, Jose Nativi-Nicolau, Cameron W. Turtle, Martha Grogan, Satish Rao, Sanjiv J. Shah, Jonathan C. Fox, Stephen B. Heitner, Jignesh Patel, Ronald M. Witteles, Mathew S. Maurer, Van N. Selby, Mazen Hanna, Rodney H. Falk, Daniel Jacoby, Daniel P. Judge
Publikováno v:
Journal of the American College of Cardiology. 74:285-295
Background Transthyretin (TTR) amyloidosis is an underdiagnosed disease caused by destabilization of TTR due to pathogenic mutations or aging. Both pathogenic and protective mutations illuminate mechanisms of disease and potential interventions. AG10
Autor:
Uma Sinha, Rick Lumpkin, Jonathan C. Fox, Jennifer L. Hellawell, Jesper Jernelius, Terry O'Reilly, Daniel D. Gretler, Satish Rao
Publikováno v:
Clinical Pharmacology in Drug Development
AG10 is a novel, potent, and selective oral transthyretin (TTR) stabilizer being developed to treat TTR amyloidosis (ATTR). This randomized, double‐blind, placebo‐controlled study evaluated safety, tolerability, pharmacokinetics, and pharmacodyna
Autor:
Ahmad Masri, Mandar Aras, Rodney H. Falk, Martha Grogan, Daniel Jacoby, Daniel P. Judge, Sanjiv Jayendra Shah, Ronald Witteles, Alan X. Ji, Paul W. Wong, Xiaofan Cao, Rebecca Vanlandingham, Leonid Katz, Uma Sinha, Jonathan C. Fox, Mathew S. Maurer
Publikováno v:
Journal of the American College of Cardiology. 79:227
Autor:
Theodore P. Cross, Alan Cohen, Bruno Gagnon, Florencia Braga Mendendez, Vincent Knobel, David Rintell, Cameron W. Turtle, Elizabeth Cross, Dena Heath, Edward Kalmykov, Jonathan C. Fox
Publikováno v:
Orphanet Journal of Rare Diseases
Orphanet Journal of Rare Diseases, Vol 16, Iss 1, Pp 1-13 (2021)
Orphanet Journal of Rare Diseases, Vol 16, Iss 1, Pp 1-13 (2021)
Background Transthyretin amyloidosis, or ATTR, is a progressive and debilitating rare proteopathy generally manifested as either transthyretin amyloid polyneuropathy (ATTR-PN) or transthyretin amyloid cardiomyopathy (ATTR-CM). Irrespective of the cli
Autor:
Kelly Lauter Roszko, Rachel I Gafni, Michael T. Collins, Jonathan C Fox, Karen A Pozo, Ramei Sani-Grosso, Iris R Hartley, Edward F. Nemeth, Ananth Sridhar
Publikováno v:
Journal of the Endocrine Society
Autosomal dominant hypocalcemia type 1 (ADH1) is a rare form of hypoparathyroidism caused by gain-of-function pathogenic variants in the gene encoding the calcium-sensing receptor (CaSR). It is characterized by variable degrees of hypocalcemia, hyper
Autor:
Kelly Lauter Roszko, Ananth Sridhar, Ramei Sani-Grosso, William D Kennedy, Iris R Hartley, Karen A Pozo, Rachel I Gafni, Jonathan C Fox, Edward F. Nemeth, Michael T. Collins
Publikováno v:
Journal of the Endocrine Society
Autosomal dominant hypocalcemia type 1 (ADH1) is a rare form of hypoparathyroidism caused by gain-of-function pathogenic variants in the gene (CASR) encoding the calcium-sensing receptor (CaSR). It is characterized by variable degrees of hypocalcemia
Autor:
Florencia Braga Menéndez, Bruno Gagnon, David Rintell, Dena Heath, Jocelyn Ashford, Jonathan C. Fox
Publikováno v:
Journal of Cardiac Failure. 26:S51
Background Patients with transthyretin amyloidosis manage a chronic, life-threatening condition that severely affects their quality of life. Although the primary symptoms and diagnostic criteria for transthyretin amyloid cardiomyopathy (ATTR-CM) and
Autor:
Naeem Chaudhri, Mahmoud Aljurf, Walid Rasheed, Syed Osman Ahmed, Tarek Owaidah, Hafiz Malhan, Fahad Almohareb, Fahad Alsharif, Jonathan C. Fox, Ayodele Alaiya, Said Y Mohamed, Zakia Shinwari, Amr Hanbali, Ghuzayel Aldawsari, Hazzaa Alzahrani
Publikováno v:
International Journal of Oncology
There is unmet need for prediction of treatment response for chronic myeloid leukemia (CML) patients. The present study aims to identify disease-specific/disease-associated protein biomarkers detectable in bone marrow and peripheral blood for objecti